Fulcrum Therapeutics (FULC) Competitors $6.83 +0.10 (+1.49%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.84 +0.00 (+0.07%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FULC vs. ADPT, SDGR, JANX, ETNB, EVO, VERA, ANIP, BHVN, TVTX, and EWTXShould you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Adaptive Biotechnologies (ADPT), Schrodinger (SDGR), Janux Therapeutics (JANX), 89BIO (ETNB), Evotec (EVO), Vera Therapeutics (VERA), ANI Pharmaceuticals (ANIP), Biohaven (BHVN), Travere Therapeutics (TVTX), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. Fulcrum Therapeutics vs. Its Competitors Adaptive Biotechnologies Schrodinger Janux Therapeutics 89BIO Evotec Vera Therapeutics ANI Pharmaceuticals Biohaven Travere Therapeutics Edgewise Therapeutics Fulcrum Therapeutics (NASDAQ:FULC) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Do institutionals and insiders have more ownership in FULC or ADPT? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer FULC or ADPT? In the previous week, Fulcrum Therapeutics had 29 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 32 mentions for Fulcrum Therapeutics and 3 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.11 beat Fulcrum Therapeutics' score of 0.48 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate FULC or ADPT? Fulcrum Therapeutics presently has a consensus target price of $7.57, indicating a potential upside of 10.86%. Adaptive Biotechnologies has a consensus target price of $11.33, indicating a potential upside of 9.71%. Given Fulcrum Therapeutics' higher possible upside, equities research analysts clearly believe Fulcrum Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is FULC or ADPT more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -74.84%. Fulcrum Therapeutics' return on equity of -31.05% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -31.05% -28.96% Adaptive Biotechnologies -74.84%-62.79%-24.55% Which has more risk and volatility, FULC or ADPT? Fulcrum Therapeutics has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Which has preferable earnings & valuation, FULC or ADPT? Fulcrum Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80M4.62-$9.73M-$1.22-5.60Adaptive Biotechnologies$178.96M8.77-$159.49M-$0.96-10.76 SummaryFulcrum Therapeutics beats Adaptive Biotechnologies on 9 of the 17 factors compared between the two stocks. Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FULC vs. The Competition Export to ExcelMetricFulcrum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$369.45M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-5.6017.7428.9323.80Price / Sales4.62309.13440.5196.33Price / CashN/A41.6335.0756.59Price / Book1.728.488.255.54Net Income-$9.73M-$55.06M$3.25B$259.97M7 Day Performance-12.55%-3.99%-3.75%-4.67%1 Month Performance-2.48%8.53%2.99%3.28%1 Year Performance-28.48%6.51%25.35%17.92% Fulcrum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FULCFulcrum Therapeutics2.2574 of 5 stars$6.83+1.5%$7.57+10.9%-28.5%$369.45M$80M-5.60100Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionADPTAdaptive Biotechnologies3.0032 of 5 stars$10.31-0.8%$10.57+2.5%+140.2%$1.58B$178.96M-10.74790Positive NewsUpcoming EarningsGap DownSDGRSchrodinger2.5992 of 5 stars$22.82+6.4%$32.75+43.5%-3.5%$1.57B$207.54M-8.68790Positive NewsUpcoming EarningsGap DownJANXJanux Therapeutics2.3971 of 5 stars$26.08-1.2%$91.89+252.3%-39.2%$1.56B$10.59M-19.1830Positive NewsUpcoming EarningsETNB89BIO2.2072 of 5 stars$10.11-3.6%$26.43+161.4%+2.8%$1.53BN/A-2.9940Upcoming EarningsAnalyst ForecastEVOEvotec1.7542 of 5 stars$3.69-13.4%$5.93+60.8%-9.0%$1.51B$862.40M0.004,827News CoverageHigh Trading VolumeVERAVera Therapeutics3.4705 of 5 stars$22.79-1.1%$65.00+185.2%-44.0%$1.47BN/A-7.6040News CoverageUpcoming EarningsShort Interest ↑ANIPANI Pharmaceuticals3.7563 of 5 stars$65.41-1.3%$78.88+20.6%+4.8%$1.44B$614.38M-51.50600Upcoming EarningsBHVNBiohaven2.3662 of 5 stars$13.81-1.7%$58.46+323.5%-58.8%$1.43BN/A-1.47239Trending NewsUpcoming EarningsTVTXTravere Therapeutics1.9056 of 5 stars$15.82-1.8%$32.14+103.2%+73.7%$1.43B$233.18M-5.63460News CoverageShort Interest ↑EWTXEdgewise Therapeutics2.4374 of 5 stars$13.39-1.1%$40.00+198.7%-11.9%$1.42BN/A-8.6460News CoverageUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies ADPT Competitors SDGR Competitors JANX Competitors ETNB Competitors EVO Competitors VERA Competitors ANIP Competitors BHVN Competitors TVTX Competitors EWTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FULC) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FULC Stock Alerts